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Stability of U-500 regular insulin in prefilled syringes
Abstract
Objective: To evaluate the stability of U-500 regular insulin in prefilled syringes stored under refrigeration for
up to 28 days.
Methods: U-500 regular insulin was drawn up in 1 mL insulin syringes in a clean, nonsterile environment to
emulate conditions of a patient’s home. Samples were assayed using a stability-indicating reverse-phase high-
performance liquid chromatography method immediately after preparation (day 0) and after 7, 14, 21, and 28
days under refrigeration. Before evaluation, all samples were diluted to a concentration of 40 units/mL in the
starting mobile phase. Stability was determined by evaluating the percentage of the initial concentration
remaining at each time point.
Results: At least 93.3% of the initial U-500 insulin concentration remained throughout the 28-day study
period, with no statistically significant changes in the amount remaining. The percent of initial concentration
remained above 97% for the first 21 days of the study.
Conclusion: A prefilled syringe with U-500 regular insulin is stable for at least 28 days when stored under
refrigeration. These data are similar to those reported for U-100 regular insulin, indicating that prefilling
syringes with U-500 insulin is a safe and effective practice for patients who are unable to accurately draw up
their own point-of-care doses.
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abstract
Objective: To evaluate the stability of U-500 regular in-
sulin in prefilled syringes stored under refrigeration for 
up to 28 days.
Methods: U-500 regular insulin was drawn up in 1 mL 
insulin syringes in a clean, nonsterile environment to 
emulate conditions of a patient’s home. Samples were 
assayed using a stability-indicating reverse-phase 
high-performance liquid chromatography method im-
mediately after preparation (day 0) and after 7, 14, 21, 
and 28 days under refrigeration. Before evaluation, all 
samples were diluted to a concentration of 40 units/mL 
in the starting mobile phase. Stability was determined 
by evaluating the percentage of the initial concentration 
remaining at each time point.
Results: At least 93.3% of the initial U-500 insulin 
concentration remained throughout the 28-day study 
period, with no statistically significant changes in the 
amount remaining. The percent of initial concentration 
remained above 97% for the first 21 days of the study.
Conclusion: A prefilled syringe with U-500 regular in-
sulin is stable for at least 28 days when stored under re-
frigeration. These data are similar to those reported for 
U-100 regular insulin, indicating that prefilling syringes 
with U-500 insulin is a safe and effective practice for pa-
tients who are unable to accurately draw up their own 
point-of-care doses.
Keywords: U-500 insulin, prefilled syringes, insulin 
stability.
J Am Pharm Assoc. 2013;53:304–306.
doi: 10.1331/JAPhA.2013.12164
stability of U-500 regular 
insulin in prefilled syringes
Melinda e. Lull, Justin J. Piacentino,  
and andrea N. traina
U-500 regular insulin is five times as concentrated as the more common U-100 regular insulin. U-500 
can be ideal for patients requiring large volumes of in-
sulin, such as those with immune responses to insulin, 
insulin receptor defects, or more commonly, severe in-
sulin resistance secondary to obesity and long-stand-
ing diabetes. Clinicians are recognizing the benefits 
of using highly concentrated insulin, and use of U-500 
insulin increased by 137% between June 2007 and June 
2009.1 Reducing the volume of solution injected also al-
lows for more consistent absorption and improved gly-
cemic control compared with use of large volumes of 
less concentrated insulin preparations.2
Currently, U-500 insulin is the only highly concen-
trated insulin product available in the United States. It 
also is the only insulin product that is not commercially 
available in a prefilled pen injection device. Some pa-
tients with diabetes may lack the vision or dexterity to 
accurately and safely draw up their own insulin doses 
using a vial and syringe.3 This may be especially true 
of patients requiring U-500 insulin, as this may be in-
dicative of more severe or progressive diabetes given 
their high degree of insulin resistance and large insulin 
dose requirements. The consequences of patient error in 
drawing up the correct dose can be much more grave 
when using concentrated insulin, as a 0.1-mL variation 
would be equivalent to a 50-unit change in dose rather 
than the 10-unit variation if a U-100 concentration insu-
lin was used. To minimize the risk of dosing errors such 
as these, it is not uncommon for nurses, home health 
aides, or other caregivers to draw up several days of 
insulin syringes for a patient and leave them in a refrig-
erator for future use. It is imperative that pharmacists, 
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especially those in the community setting, be able to 
confidently counsel their patients on the ability to safely 
prefill their insulin syringes with U-500 insulin. The 
question of maintained efficacy with U-500 insulin in a 
prefilled syringe is one that is occurring with growing 
frequency given the increased use of U-500 insulin for 
the management of diabetes.
The stability of U-100 insulin preparations in pre-
filled syringes has been well studied. Tarr et al.4 de-
termined that U-100 regular insulin remains stable for 
28 days at room temperature and under refrigeration. 
Dunbar and Simon5 reported that U-100 regular insu-
lin maintains immunologic and biologic potency for at 
least 2 weeks. Zell and Paone6 found that U-100 regular 
insulin is stable under refrigeration in polypropylene 
syringes for at least 14 days. The previous two studies 
did not examine stability past 14 days. Unfortunately, 
no data currently exist regarding the duration of stabil-
ity of U-500 regular insulin when stored in prefilled sy-
ringes. Because the stability of different concentrations 
of protein solutions can vary over time,7 data regard-
ing the stability of U-500 may differ from that of U-100; 
therefore, an investigation of U-500 insulin is warrant-
ed.
objective
The objective of this study was to determine if U-500 
insulin is stable when stored in prefilled syringes at 4°C 
for up to 28 days.
Methods
Preparation of samples
The stability U-500 insulin (Humulin R U-500 Regu-
lar Insulin, Eli Lilly, Indianapolis, IN; lot A849585A, 
expiration February 2013) was evaluated after storage 
in 0.3 mL 29 gauge × 0.5 in polypropylene insulin sy-
ringes (BD Ultra-Fine Needle insulin syringe, Becton 
Dickinson, Franklin Lakes, NJ). Using careful technique 
on a clean but nonsterile laboratory bench, 0.25 mL (125 
units) of U-500 insulin was drawn into each syringe (n = 
3 for each time point). Three samples were analyzed im-
mediately to establish baseline (day 0) stability values. 
The remaining 12 syringes were kept capped inside an 
open tray in a laboratory refrigerator (3–5°C). At days 
7, 14, 21, and 28, three of the stored syringes were re-
moved for analysis. Sample also was drawn for a forced 
degradation sample. In preparation for reverse-phase 
(RP) high-performance liquid chromatography (HPLC) 
analysis, each sample was diluted to an expected con-
centration of 40 units/mL in the starting mobile phase 
according to previously published protocols.4
HPLC method
The RP-HPLC method previously described for use in 
U-100 stability studies4,8 was adapted for use with mod-
ifications according to standard insulin HPLC protocols 
used by the column manufacturer (Ascentis Express 
Peptide ES-C18 HPLC Columns, Sigma-Aldrich, St. 
Louis, MO). The HPLC instrument included a constant-
flow solvent delivery system, variable volume injector, 
degasser, autosampler, and an ultraviolet light detector 
set to 214 nm (HPLC 2010A HT; Shimadzu Scientific In-
struments, Marlborough, MA). The column used was 
a C18 column (4.6 × 30 mm) with a 300-Å pore size and 
5-µm particle size (BioBasic C18 column; Thermo Fisher 
Scientific, Waltham, MA). Throughout the runs, the 
column was maintained at 40°C. Shimadzu LC Solu-
tion software (version 1.25; Shimadzu Scientific Instru-
ments) was used for data collection and processing.
The mobile phase was a linear gradient of mobile 
phase A (deionized water and acetonitrile [90:10 v/v] 
with 0.1% trifluoroacetic acid) and mobile Phase B (de-
ionized water and acetonitrile [25:75 v/v] with 0.1% tri-
fluoroacetic acid). A linear gradient was used between 
two mobile phases, with a starting ratio of 75% A and 
25% B, increasing to 40% B (60% A) over 15 minutes. The 
ratio then was programmed to increase to 60% B (40% 
A) from minute 15 to minute 20 to elute any remaining 
material from the column. A rinse then was performed 
with deionized water and methanol (1:1 v/v). Injections 
of 10 μL samples were eluted at a rate of 1.5 mL/min, 
with an average retention time of 4.8 ± 0.17 minutes. 
Each of the three replicates at each time point was run in 
duplicate on the HPLC. A standard curve of concentra-
tions ranging from 0 to 100 units/mL was prepared to 
establish the linearity of the peak area versus concentra-
tion. The standard curve was linear (r2 = 0.991) over the 
concentration range. The inter- and intraday variability 
of the RP-HPLC assay (as represented by coefficient of 
variation) were 0.23% and 0.05%, respectively.
Stability-indicating ability of the method was deter-
mined through the assay of a forced degradation sam-
ple. The forced degradation sample was prepared by 
adjusting the insulin to pH 2 with 10 N HCl and degrad-
ing the sample at 37°C for 96 hours. RP-HPLC analysis 
was conducted for this degraded sample in duplicate 
using the same method described above. The degraded 
sample showed decreased area of the main peak (52.3% 
remaining), and an unidentified degradation product 
peak was observed approximately 0.7 minutes after 
the insulin peak that is almost equal in area to the main 
insulin peak. No significant peak was observed at this 
time in other nondegraded samples.
Data analysis
The mean (±SD) area under the curve for insulin peak 
1 was calculated. Mean values for days 7, 14, 21, and 28 
were adjusted to a percent of the average day 0 value 
(measured at 500 units/mL; diluted sample measured 
at 40 units/mL). A one-way analysis of variance with a 
Bonferroni post hoc test then was performed to detect 
any statistically significant changes in insulin levels us-
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ing SigmaPlot version 11.2 (Systat Software, San Jose, 
CA). P < 0.05 was considered statistically significant.
Results
Under RP-HPLC, the area under the curve for peak 1 
(retention time 4.8 ± 0.17 minutes) represents pharma-
ceutically active U-500. Samples at all measured time 
points retained at least 93.3% of the initial U-500 con-
centration (Table 1). Differences in percent of initial 
concentration remaining between any time point were 
not statistically significant (P = 0.130). This suggests a 
minimal loss of product due to degradation. Degrada-
tion products, not observed after 28 days of storage, can 
be seen in the forced degradation sample with a reduc-
tion in parent compound and the appearance of a sec-
ond peak at 5.5 minutes.
Evidence in the literature is lacking regarding the 
definition of stability of insulin in the absence of statisti-
cally significant changes. In clinical practice, insulin ad-
justments often are made in increments of 10% to 20% 
of the given dose. Keeping this principal in mind, we 
considered stability to be maintained if at least 90% of 
the product remained at a given time point. Despite the 
fivefold increase in insulin concentration, it appears that 
U-500 insulin is at least as stable as U-100 insulin.4 At 
least 93% of the initial product remains when prefilled 
into syringes and refrigerated at 4°C with no statisti-
cally significant reductions in insulin concentration. A 
slight drop in percent remaining at day 7 is not statisti-
cally different from any of the other values and remains 
well above the 90% cutoff. The sample size gives ade-
quate statistical power (>0.8); however, a larger sample 
size may help normalize the values. In addition, future 
studies should verify the sterility of U-500 insulin when 
drawn and stored in nonsterile conditions, though the 
sterility of U-100 insulin in prefilled syringes has been 
established.4
The prescribing information for U-500 insulin states 
that it must be used within 31 days of initial use or oth-
erwise should be discarded.9 This should be taken into 
consideration when preparing prefilled syringes of 
U-500 insulin for subsequent storage. Additional con-
sideration should be given to safely labeling and stor-
ing the syringes after they are prefilled because patients 
often have multiple doses of insulin. In practice, we rec-
ommend storing each dose in a different container, with 
each container in a different location in the refrigerator 
(e.g., prebreakfast dose on the top shelf, prelunch dose 
on the bottom shelf, predinner dose in the door). Care-
givers also should be educated to label all insulin doses. 
We typically recommend large white mailing labels 
(approximately 2 in × 3 in). These labels can be attached 
to the barrel of the syringe with the number of units 
written in large print on one side and the meal written 
on the other. These measures are extremely important 
to minimize the risk of the patient injecting the wrong 
dose of their highly concentrated insulin and risking 
hypo- or hyperglycemia. It also is imperative that on the 
label, caregivers write in smaller print (for their use) the 
date that the U-500 vial was originally opened and the 
date the syringe was prefilled. These dates should be 
checked regularly to ensure prefilled syringes are used 
promptly and expired insulin is never administered by 
the patient.
conclusion
U-500 insulin in prefilled syringes stored at 4°C is 
stable for up to 28 days. Prefilled syringes containing 
U-500 insulin and stored at 4°C for up to 28 days can 
be used confidently by caregivers for treating patients 
with diabetes with severe insulin resistance who are 
unable to independently manage a traditional vial and 
syringe.
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Table 1. Stability of U-500 Insulin in syringes at 4°C
Day
Percent initial concentrationa remaining 
Mean ± SDb
7 97.848 ± 0.629
14 99.432 ± 3.857
21 99.906 ± 2.389
28 93.317 ± 2.379
aInitial drug concentration = 500 units/mL. 
bMean ± SD of three biological replicates (n = 3).
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